UpTempo℠ Antibody: A Streamlined Platform Process to Accelerate Biotherapeutics from Gene to Clinic

Date: May 8, 2024
Time: 11:00 am  EDT

Speed to clinic is a top priority for the majority of biopharmaceutical companies. Harmonizing technological innovation with platform biomanufacturing development and knowledge can address the time and cost barriers for protein biologics while producing stable, high-expressing antibody-based therapeutics. Catalent’s UpTempo℠ Antibody platform process combines industry-leading GPEx® cell line development technology with streamlined, phase-appropriate drug substance development to deliver products from early-stage development through GMP manufacturing. In addition, UpTempo℠ Antibody provides a flexible platform process for multi-chain expression and scalable manufacturing with consistent performance and product quality – all key aspects to deliver biotherapeutics on an expedited timeline for clinical trials.